Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicity

• Published in: PloS one 2017-02, Vol.12 (2), p.e0171294
• Main Authors: Montané, Eva, Barriocanal, Ana Maria, Arellano, Ana Lucía, Valderrama, Angelica, Sanz, Yolanda, Perez-Alvarez, Nuria, Cardona, Paula, Vilaplana, Cristina, Cardona, Pere-Joan
• Format: Article
• Language: English
• Subjects: Adult; Adults; Biology and Life Sciences; CD25 antigen; Clinical trials; Control methods; Dietary Supplements - adverse effects; Double-Blind Method; Double-blind studies; Drinking water; Effector cells; Female; Hospitals; Humans; Immunogenicity; Infections; Infectious diseases; Latent Tuberculosis - diet therapy; Latent Tuberculosis - immunology; Lesions; Lymphocytes; Lymphocytes T; Male; Medicine and Health Sciences; Microbial Viability; Mycobacterium; Mycobacterium - immunology; Mycobacterium tuberculosis; New species; Pain; Pathogens; Pharmacology; Pilot Projects; Placebos; Population (statistical); Probiotics - administration & dosage; Probiotics - adverse effects; Randomization; Research and Analysis Methods; Risk reduction; Toxicology; Tuberculosis; Young Adult
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0171294

Nyaditum resae® (NR) is a galenic preparation of heat-killed Mycobacterium manresensis, a new species of the fortuitum complex, that is found in drinkable water, and that has demonstrated to protect against the development of active TB in a murine experimental model that develop human-like lesions. Double-blind, randomized, placebo-controlled Clinical Trial (51 volunteers included). Two different doses of NR and a placebo were tested, the randomization was stratified by Latent Tuberculosis Infection (LTBI)-positive (n = 21) and LTBI-negative subjects (n = 30). Each subject received 14 drinkable daily doses for 2 weeks. All patients completed the study. The 46.3% of the overall reported adverse events (AE) were considered related to the investigational treatment. None of them were severe (94% were mild and 6% moderate). No statistical differences were found when comparing the median number of AE between the placebo group and both treatment groups. The most common AE reported were gastrointestinal events, most frequently mild abdominal pain and increase in stool frequency. Regarding the immunogenic response, both LTBI-negative and LTBI-positive volunteers treated with NR experienced a global increase on the Treg response, showed both in the population of CD25+CD39-, mainly effector Treg cells, or CD25+CD39+ memory PPD-specific Treg cells. This clinical trial demonstrates an excellent tolerability profile of NR linked to a significant increase in the population of specific effector and memory Tregs in the groups treated with NR in both LTBI-positive and negative subjects. NR shows a promising profile to be used to reduce the risk of active TB.